More on ANTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.71 |
|
|||
| Open | $1.71 | ||||
| 52 Wk High | $48.59 | ||||
| 52 Wk Low | $40.72 | ||||
| Day High | $2.97 | ||||
| Day Low | $1.57 | ||||
| P/E | N/A | ||||
| EPS | $-0.01 | ||||
| Volume | 6,973,270 | ||||
- Form 4 AN2 Therapeutics, Inc. For: Mar 03 Filed by: Williams Sarah Joanne
- AN2 Therapeutics plans phase 2 trial for blood cancer drug
- AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Eizen Joshua M
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Day Lucy
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Williams Sarah Joanne
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Easom Eric
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Chanda Sanjay
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Marks Gilbert Lynn
- Form 4 AN2 Therapeutics, Inc. For: Feb 20 Filed by: Readnour Robin Shane
Entities mentioned with ANTX
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- IPO | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
